Glucagon-like peptide-1 receptor agonists in adults with overweight/obesity and alcohol use disorder: A retrospective cohort study.
GLP-1 medications show associations with both weight loss and reduced alcohol use in people with alcohol use disorder, suggesting a potential dual benefit worth studying further.
Penn State retrospective cohort investigates GLP-1 RA prescribing in overweight/obese adults with co-existing alcohol use disorder, finding associations with reduced alcohol use alongside weight loss. The NIH NIDA/NIAAA author (Leggio L) lends credibility to this hypothesis; findings are exploratory given non-randomized design but add to emerging evidence for GLP-1 RA as a potential dual-indication therapy.
What the study was
- Study design
- Retrospective cohort study
- Category
- Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
- Maturity
- Exploratory
- Journal
- Eur J Intern Med
Why it surfaced
Novel real-world hypothesis generation for GLP-1 RA in AUD; NIH NIDA and Penn State authorship; published in Eur J Intern Med; abstract truncated, full results require primary paper access. High novelty score justified by unpublished clinical indication. Requires prospective RCT confirmation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.